| h-debate-0df96d9a759 | Dual-Targeting BBB Shuttle-Amyloid Antibodies | 0.00 | 0.55 | TFRC (transferrin receptor), APP/Aβ | proposed | 2026-04-28 | sda-2026-04-01-gap-008 |
| h-debate-fcc43254015 | Focused Ultrasound-Enhanced Antibody Delivery | 0.00 | 0.55 | APP/Aβ, tight junction proteins (claudins, occludin) | proposed | 2026-04-28 | sda-2026-04-01-gap-008 |
| h-debate-7a1478ba484 | Peptide Mimetics to Block Domain Interaction | 0.00 | 0.55 | APOE | proposed | 2026-04-28 | sda-2026-04-01-gap-010 |
| h-debate-067c9990db5 | Selective APOE4 Degradation and Replacement | 0.00 | 0.55 | APOE | proposed | 2026-04-28 | sda-2026-04-01-gap-010 |
| h-debate-083bf9f93d2 | Chaperone-Mediated APOE4 Refolding Therapy | 0.00 | 0.55 | APOE | proposed | 2026-04-28 | sda-2026-04-01-gap-010 |
| h-debate-18a83bb5a4e | Small Molecule Domain Disruptors for APOE4 Normalization | 0.00 | 0.55 | APOE | proposed | 2026-04-28 | sda-2026-04-01-gap-010 |
| h-debate-b4326ad0de4 | Allosteric Modulators Targeting Lipid Binding Enhancement | 0.00 | 0.55 | APOE | proposed | 2026-04-28 | sda-2026-04-01-gap-010 |
| h-debate-c417be99639 | Targeted Cysteine Substitution Gene Therapy | 0.00 | 0.55 | APOE | proposed | 2026-04-28 | sda-2026-04-01-gap-010 |
| h-debate-f75956b4a67 | Lipid Co-factor Supplementation Therapy | 0.00 | 0.55 | APOE | proposed | 2026-04-28 | sda-2026-04-01-gap-010 |
| h-debate-2e6b77baccd | Cross-Seeding Autophagy Specificity Enhancement | 0.00 | 0.55 | SQSTM1 | proposed | 2026-04-28 | sda-2026-04-01-gap-011 |
| h-debate-ff417190bef | Glymphatic-Autophagy Coupling Enhancement | 0.00 | 0.55 | AQP4 | proposed | 2026-04-28 | sda-2026-04-01-gap-011 |
| h-debate-c0db7ae9bb4 | Stress Granule-Autophagy Interception Therapy | 0.00 | 0.55 | G3BP1 | proposed | 2026-04-28 | sda-2026-04-01-gap-011 |
| h-debate-b3b28c95ed6 | Lysosomal pH Microdomains Restoration | 0.00 | 0.55 | ATP6V1A | proposed | 2026-04-28 | sda-2026-04-01-gap-011 |
| h-debate-722e9da1535 | Lipid Raft Autophagy Receptor Reorganization | 0.00 | 0.55 | APOE | proposed | 2026-04-28 | sda-2026-04-01-gap-011 |
| h-debate-aff846dc0c3 | Retinal-Derived Neurotrophic Factor Delivery | 0.00 | 0.55 | BDNF, GDNF, TrkB, GFRα1 | proposed | 2026-04-28 | sda-2026-04-01-gap-012 |
| h-debate-9168ece51e3 | Voice-Guided Vagal Nerve Stimulation | 0.00 | 0.55 | CHAT, α7nAChR, TNF-α | proposed | 2026-04-28 | sda-2026-04-01-gap-012 |
| h-debate-27ffadf1dcb | Retinal Microvascular Neuroprotection | 0.00 | 0.55 | VEGFA, ANGPT2, CDH5 | proposed | 2026-04-28 | sda-2026-04-01-gap-012 |
| h-debate-d0b38913d62 | Smartphone-Detected Cognitive Load Modulation | 0.00 | 0.55 | COMT, CACNA1C, GRIN2B | proposed | 2026-04-28 | sda-2026-04-01-gap-012 |
| h-debate-c08c1a4f049 | Circadian-Speech Synchronization Therapy | 0.00 | 0.55 | CLOCK, BMAL1, MTNR1A/1B | proposed | 2026-04-28 | sda-2026-04-01-gap-012 |
| h-debate-84e1e96a9c5 | Gait-Motor Cortex Plasticity Enhancement | 0.00 | 0.55 | BDNF, CREB1, synapsin family genes | proposed | 2026-04-28 | sda-2026-04-01-gap-012 |
| h-debate-5dfaee2f11c | Circadian-Timed Senolytic Therapy | 0.00 | 0.55 | CLOCK, ARNTL, CDKN2A, CDKN1A | proposed | 2026-04-28 | sda-2026-04-01-gap-013 |
| h-debate-e7510405c8c | Extracellular Vesicle-Mediated SASP Disruption | 0.00 | 0.55 | IL1B, TNF, IL6, MIR146A | proposed | 2026-04-28 | sda-2026-04-01-gap-013 |
| h-debate-01b2d371572 | Astrocyte-Specific Senolytic Delivery via GFAP-Targeted Nanoparticles | 0.00 | 0.55 | GFAP, SRC, PIK3CA | proposed | 2026-04-28 | sda-2026-04-01-gap-013 |
| h-debate-510f995a6dc | Microglial Senescence Reversal Through TREM2 Agonism | 0.00 | 0.55 | TREM2, TYROBP, SYK | proposed | 2026-04-28 | sda-2026-04-01-gap-013 |
| h-debate-2d861158748 | Senolytic-Primed Autophagy Enhancement | 0.00 | 0.55 | MTOR, ULK1, BCL2L1 | proposed | 2026-04-28 | sda-2026-04-01-gap-013 |
| h-debate-e45b1cf8f2e | p21-Targeted Proteolysis-Targeting Chimeras (PROTACs) | 0.00 | 0.55 | CDKN1A | proposed | 2026-04-28 | sda-2026-04-01-gap-013 |
| h-debate-0d914b5bd78 | Dual BCL-2/CDK4/6 Inhibition for Enhanced Senolytic Efficacy | 0.00 | 0.55 | BCL2, CDK4, CDK6 | proposed | 2026-04-28 | sda-2026-04-01-gap-013 |
| h-debate-5810cce4cad | Mitochondrial SPM Synthesis Compartmentalization | 0.00 | 0.55 | ALOX15 | proposed | 2026-04-28 | sda-2026-04-01-gap-014 |
| h-debate-418a764b626 | Astrocyte-Microglial SPM Shuttle System Enhancement | 0.00 | 0.55 | ALOX15, GJA1 | proposed | 2026-04-28 | sda-2026-04-01-gap-014 |
| h-debate-3622e2b7533 | Blood-Brain Barrier SPM Transporter Upregulation | 0.00 | 0.55 | SLCO1A4, SLC27A1 | proposed | 2026-04-28 | sda-2026-04-01-gap-014 |
| h-debate-cb5a8619ae2 | Senescent Cell-Derived SPM Antagonist Neutralization | 0.00 | 0.55 | CDKN2A, TP53 | proposed | 2026-04-28 | sda-2026-04-01-gap-014 |
| h-debate-4e334c6b214 | Microglial SPM Receptor Priming Therapy | 0.00 | 0.55 | FPR2, GPR32, GPR18 | proposed | 2026-04-28 | sda-2026-04-01-gap-014 |
| h-debate-6d024835a85 | Circadian SPM Synthesis Restoration | 0.00 | 0.55 | CLOCK, BMAL1, ALOX15 | proposed | 2026-04-28 | sda-2026-04-01-gap-014 |
| h-debate-34ee7cde288 | Epigenetic SPM Pathway Reprogramming | 0.00 | 0.55 | DNMT1, HDAC2 | proposed | 2026-04-28 | sda-2026-04-01-gap-014 |
| h-debate-cfd3d2d7931 | Cannot Generate Hypotheses | 0.00 | 0.55 | N/A | proposed | 2026-04-28 | sda-2026-04-01-gap-9137255b |
| h-debate-4112ce83fa9 | CRISPR-dCas9 Epigenetic Reprogramming of Stress Granules | 0.00 | 0.55 | TDP43 + FUS | proposed | 2026-04-28 | sda-2026-04-01-002 |
| h-debate-6b41b68e47b | Mitochondrial-Lysosomal Contact Site Modulators | 0.00 | 0.55 | VDAC1 + LAMP1 | proposed | 2026-04-28 | sda-2026-04-01-002 |
| h-debate-ca4b31f76b1 | Engineered Extracellular Vesicle Therapy with Synthetic Biology | 0.00 | 0.55 | GBA + HSP70 + LAMP2A | proposed | 2026-04-28 | sda-2026-04-01-002 |
| h-debate-58aa0aeaa66 | Pharmacological Chaperone-Mediated Selective Autophagy | 0.00 | 0.55 | GBA + SQSTM1 | proposed | 2026-04-28 | sda-2026-04-01-002 |
| h-debate-63f66fbf6fa | Temporal Metabolic Rewiring with Circadian Modulators | 0.00 | 0.55 | NR1D1 + CLOCK + TFEB | proposed | 2026-04-28 | sda-2026-04-01-002 |
| h-debate-9ee6e75a400 | Lipid Raft Disruptors with Membrane Fluidizers | 0.00 | 0.55 | GBA + SNCA | proposed | 2026-04-28 | sda-2026-04-01-002 |
| h-debate-822f893c3e0 | Selective Glucosylceramide Synthase Inhibition with Lysosomal Enhancement | 0.00 | 0.55 | UGCG + TFEB | proposed | 2026-04-28 | sda-2026-04-01-002 |
| h-debate-2cfb0990126 | Qualitative research integration enhances patient-centered neurodegeneration stu | 0.00 | 0.55 | N/A - qualitative methodology | proposed | 2026-04-28 | sda-2026-04-01-gap-auto-fd6b1635d9 |
| h-debate-bbe333ca21a | Power analysis optimization reduces false negatives in neurodegeneration trials | 0.00 | 0.55 | N/A - statistical methodology | proposed | 2026-04-28 | sda-2026-04-01-gap-auto-fd6b1635d9 |
| h-debate-78bb6479d31 | Standardized qPCR protocols improve neurodegeneration biomarker reproducibility | 0.00 | 0.55 | N/A - methodological intervention | proposed | 2026-04-28 | sda-2026-04-01-gap-auto-fd6b1635d9 |
| h-debate-1ac93d6e5c2 | Sleep-Dependent Synaptic Plasticity Restoration | 0.00 | 0.55 | N/A (Plasticity Networks) | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-18cf98ca |
| h-debate-ef41473f123 | Metabotropic Glutamate Receptor-Based Sleep Stabilization Therapy | 0.00 | 0.55 | GRM5 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-18cf98ca |
| h-debate-35185d474ec | Circadian-Metabolic Coupling for Neuroprotection | 0.00 | 0.55 | CLOCK/BMAL1 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-18cf98ca |
| h-debate-f42425b5b75 | Trauma-Induced Sleep Disruption as Therapeutic Window | 0.00 | 0.55 | N/A (Sleep Systems) | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-18cf98ca |
| h-debate-0c167479fbf | Biofluid-Guided Predictive Sleep Intervention | 0.00 | 0.55 | N/A (Biomarker Panel) | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-18cf98ca |